Loading…
Chinese pharmaceutical group selling branded generics and innovative drugs in oncology, CNS and anti-infection.
Chinese pharmaceutical group selling branded generics and innovative drugs in oncology, CNS and anti-infection.
Sells to Chinese hospitals, mostly through distributors, and its older branded generics face price pressure from state bulk-buying tenders. Newer innovative drugs carry the shift in mix, and licensing deals with other drugmakers add upfront and milestone payments to product income.
In one line: A mid-size Chinese pharma mixing generics and specialty drugs.
Moat: narrow (brand, distribution). Established hospital sales network and legacy branded-generic portfolio.
Headquarters: Nanjing, China · Founded: 1995 · Employees: 7,038
Size Simcere Pharmaceutical (2096.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $3.63B, the 308th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$11.09 on 6 Nov 2026.
Performance Over six months the shares fell 7.3%, against +4.1% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 27.2% over the last twelve months (peer median +8.7%); the operating margin is 17.8% (peer median 14.4%).
Valuation It trades at 14.3× forward earnings against a peer median of 21.8× (4th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.4 points above its cost of capital (6.4% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$9.76B | HK$8.38B | HK$7.19B | HK$7.30B | HK$7.35B |
| Revenue growth | — | +17% | -1% | -1% | — |
| Gross profit | HK$8.09B | HK$6.84B | HK$5.77B | HK$5.51B | HK$5.81B |
| EBITDA | HK$2.20B | HK$1.75B | HK$1.31B | HK$944M | HK$834M |
| Net income | HK$1.76B | HK$1.46B | HK$783M | HK$790M | HK$1.08B |
| Free cash flow | HK$2.47B | HK$1.84B | HK$1.19B | -HK$47.3M | HK$1.48B |
| Capital expenditure | HK$1.34B | HK$935M | HK$841M | HK$1.08B | HK$788M |
| Total debt | n/a | HK$1.33B | HK$1.32B | HK$1.67B | HK$1.81B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Simcere Pharmaceutical 2096.HK | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% |
| China Resources Pharmaceutical 3320.HK | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% |
| Livzon Pharmaceutical 1513.HK | $3.69B | -11% | -10% | 19% | 11.3× | -7.7% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2096.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.7% | +5.2% | 8th lowest of 21 |
| 6-month return | -7.3% | +4.1% | 7th lowest of 20 |
| Distance from 52-week high | -22.9% | -24.8% | 10th highest of 21 |
| Revenue growth (TTM) | +27.2% | +8.7% | 6th highest of 19 |
| Operating margin | 17.8% | 14.4% | 7th highest of 17 |
| Forward P/E | 14.3× | 21.8× | 4th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -2.8% | 3.9% | 5th least demanding of 15 |
| Growth delivered (Del g) | +10.6% | +9.9% | 8th highest of 15 |
| Hurdle (Req g minus delivered) | -13.4 pp | -10.1 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +9.4 pp | +4.3 pp | 5th highest of 16 |
| EV / EBITDA | 12.1× | 19.7× | 4th cheapest of 11 |
| Net debt / EBITDA | -0.8× | 2.3× | 2nd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% | +10.6% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 4.0× | -4.5% | -1.0% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% | +19.4% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 43.4× | 20.5% | +98.4% |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.69B | -11% | -10% | 19% | 11.3× | -7.7% | +2.0% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% | +4.5% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% | +7.8% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% | +12.0% |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% | +3.2% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% | +5.9% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 23.8× | 15.2% | +61.4% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | n/a | 31.9% | +159.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.37B | +30% | +9% | 3% | 159.9× | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.35B | +19% | +26% | 13% | n/a | 56.9% | +4.2% |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |